AMSBIO announce the availability of recombinant proteins and antibodies for detection of <strong><span style="color: #ff9900;"><a style="color: #ff9900;" href="https://www.who.int/health-topics/coronavirus">Coronavirus</a> </span></strong>(COVID-19) and related RNA viruses.

Historically strains of Coronavirus able to infect humans (HCoV-OC43, HCoV-229E, HCoV-NL63, and HCoVHKU1) were not highly pathogenic and only caused mild respiratory illness. By comparison more recent strains - SARS-CoV, MERS-CoV and COVID-19 that emerged in Wuhan, China at the end of 2019 are highly pathogenic resulting in large scale pandemics.

<a href="https://www.who.int/health-topics/coronavirus"><strong><span style="color: #ff9900;">Coronaviruses</span></strong></a> are a group of enveloped positive-stranded RNA viruses, which contains four structural proteins including spike glycoprotein, envelope protein, membrane protein, and nucleocapsid protein. Spike glycoprotein is the most important surface protein of <a href="https://www.who.int/health-topics/coronavirus"><strong><span style="color: #ff9900;">coronavirus</span></strong></a>, which can mediate the entrance to human respiratory epithelial cells by interacting with cell surface receptor angiotensin-converting enzyme 2 (ACE2). The spike glycoprotein includes two regions, S1 and S2, where S1 is for host cell receptor binding and S2 is for membrane fusion. Spike glycoprotein is a key target for vaccines, therapeutic antibodies, and diagnostics.

To facilitate research into developing antiviral drugs, vaccines and diagnostics - AMSBIO is able to supply high quality 2019-nCoV full length S protein, S1 protein and human ACE2 protein based on the HEK293 human cell expression platform. The binding activity of these products has been verified by Surface Plasmon Resonance (SPR) and Biolayer Interferometry (BLI) technologies. Also available are antibodies, including antibody pairs against coronavirus for ELISA, PCR detection kit for SARS-CoV-2 and ACE2 expression vectors, shRNA vectors and <a href="https://geneticliteracyproject.org/2020/03/10/fighting-the-coronavirus-outbreak-with-genetic-sequencing-crispr-and-synthetic-biology/"><strong><span style="color: #ff9900;">CRISPR</span></strong> kits.</a>

For further information on recombinant proteins, antibodies and kits for detection of Coronavirus – COVID-19 (2019-nCoV) please visit www.amsbio.com/coronavirus.aspx or contact AMSBIO on +44-1235-828200 / +1-617-945-5033 / info@amsbio.com.

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics.

For drug discovery research, AMSBIO offers assays, recombinant proteins and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognised as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cell and cell therapy applications these include high quality solutions for viral delivery (lentivirus, adenovirus and adeno-associated virus) in addition to GMP cryopreservation technology.